• Home
  • NEW DAY MEDICINE
  • 1 (87) 2026
  • 48 -1 (87) 2026 - Abdikarimova A.Kh., Usmonov B.B. - HUMAN PAPILLOMAVIRUS–ASSOCIATED OROPHARYNGEAL CANCER: CLINICAL PROFILE, PROGNOSTIC FACTORS, AND IMPACT ON TREATMENT STRATEGY

48 -1 (87) 2026 - Abdikarimova A.Kh., Usmonov B.B. - HUMAN PAPILLOMAVIRUS–ASSOCIATED OROPHARYNGEAL CANCER: CLINICAL PROFILE, PROGNOSTIC FACTORS, AND IMPACT ON TREATMENT STRATEGY

HUMAN PAPILLOMAVIRUS–ASSOCIATED OROPHARYNGEAL CANCER: CLINICAL PROFILE, PROGNOSTIC FACTORS, AND IMPACT ON TREATMENT STRATEGY

Abdikarimova A.Kh. - Republican specialized scientific and practical medical center of oncology and radiology Bukhara branch Uzbekistan, Tashkent State Medical University

Usmonov B.B. - Republican specialized scientific and practical medical center of oncology and radiology Bukhara branch Uzbekistan, Tashkent State Medical University

Xasanov A.I. - Republican specialized scientific and practical medical center of oncology and radiology Bukhara branch Uzbekistan

Resume

Human papillomavirus (HPV)–associated oropharyngeal cancer has recently been recognized as a distinct oncological subtype with pronounced clinical and prognostic significance. These tumors differ substantially from HPV-negative oropharyngeal cancer in clinical presentation, morphological features, sensitivity to treatment, and survival outcomes. This literature review analyzes current data on the clinical profile of HPV-associated oropharyngeal cancer, characteristics of regional metastasis, immunohistochemical and molecular markers (p16, viral genotype, viral load, physical status of the virus), as well as the impact of these factors on prognosis and treatment decision-making. The role of prognostic stratification based on HPV status, the TNM 8th edition staging system, and the concepts of treatment de-escalation in clinical practice are highlighted. The importance of an integrated clinical and molecular approach in the management of HPV-associated oropharyngeal cancer is emphasized.

Keywords: oropharyngeal cancer, human papillomavirus, clinical profile, prognosis, p16, viral load, treatment strategy, de-escalation.

First page

276

Last page

282

For citation:Abdikarimova A.Kh., Usmonov B.B., Xasanov A.I. - HUMAN PAPILLOMAVIRUS–ASSOCIATED OROPHARYNGEAL CANCER: CLINICAL PROFILE, PROGNOSTIC FACTORS, AND IMPACT ON TREATMENT STRATEGY//New Day in Medicine 1(87)2026 276-282 https://newdayworldmedicine.com/en/new_day_medicine/1-87-2026

List of References

  1. Ang K.K., et al. HPV and survival in OPSCC. N Engl J Med. 2010;363:24–35.
  2. Bernard H.U., et al. Classification of papillomaviruses. Virology. 2010;401:70–79.
  3. Chaturvedi A.K., et al. Human papillomavirus and rising oropharyngeal cancer incidence. J Clin Oncol. 2011;29:4294–4301.
  4. Doorbar J., et al. Biology of HPV. Vaccine. 2012;30:F55–F70.
  5. Fakhry C., et al. Improved survival of HPV-positive OPSCC. J Natl Cancer Inst. 2008;100:261–269.
  6. Fakhry C., et al. Response to therapy. J Clin Oncol. 2014;32:3365–3373.
  7. Gillison M.L., Chaturvedi A.K., Anderson W.F., Fakhry C. Epidemiology of human papillomavirus–positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33:3235–3242.
  8. Gillison M.L., et al. Tobacco and risk. J Clin Oncol. 2012;30:2102–2111.
  9. Goldenberg D., et al. Cystic nodal metastasis. Arch Otolaryngol Head Neck Surg. 2008;134:654–660.
  10. Holzinger D., et al. Biomarkers and prognosis. J Clin Oncol. 2012;30:3075–3083.

    file

    download